Rezumat articol ediţie STUDIA UNIVERSITATIS BABEŞ-BOLYAI

În partea de jos este prezentat rezumatul articolului selectat. Pentru revenire la cuprinsul ediţiei din care face parte acest articol, se accesează linkul din titlu. Pentru vizualizarea tuturor articolelor din arhivă la care este autor/coautor unul din autorii de mai jos, se accesează linkul din numele autorului.

 
       
         
    STUDIA CHEMIA - Ediţia nr.2 din 2023  
         
  Articol:   DESIGN, SYNTHESIS, CHARACTERIZATION, BIOACTIVITY AND MOLECULAR DOCKING STUDIES OF NOVEL SULFAMIDES.

Autori:  ALI NADERI, AKIN AKINCIOĞLU, AHMET ÇAĞAN, SÜLEYMAN GÖKSU, PARHAM TASLIMI, İLHAMI GÜLÇIN.
 
       
         
  Rezumat:  
DOI: 10.24193/subbchem.2023.2.10

Published Online: 2023-06-30
Published Print: 2023-07-30
pp. 145-168

VIEW PDF

FULL PDF


Starting from commercially available 4-phenylbutanoic acids, a series of novel sulfamides were synthesized and investigated for their inhibition properties on the human carbonic anhydrase I and II (hCA I and II), acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. SAR was also evaluated with molecular docking study. These new compounds were tested against hCA I and hCA II, BChE, and AChE. The majority of the synthetic compounds were more effective against AChE than tacrine, a common inhibitor. Additionally, tacrine was not the only synthetic substance that was more effective against BChE. The obtained results revealed that N,N-dimethyl-[3-(2,4-dimethoxyphenyl)propyl]sulfamide 25, with Ki of 94.22±42.37 nM against AChE and Ki of 230.91±46.22 nM against BChE, was the most potent compound against cholinesterase enzymes. These recently created substances were tested for their ability to inhibit hCA I and II isoforms. In comparison to the conventional inhibitor acetazolamide, the majority of produced sulfamide derivatives 25–29 also inhibited these investigated isoforms. In particular, sulfamide derivatives 25-29 with substituents N,N-dimethyl-[3-(3,5-dimethoxyphenyl)propyl]sulfamide 26 and N,N-dimethyl-[3-(3,4-dimethoxyphenyl)propyl]sulfamide 27 emerged as the most potent hCA inhibitors.

Keywords: Synthesis; 3-phenylbutylamine; sulfamide; biological effects; molecular docking
 
         
     
         
         
      Revenire la pagina precedentă